Sarepta Therapeutics, Inc.

NasdaqGS:SRPT 주식 리포트

시가총액: US$2.2b

Sarepta Therapeutics 과거 순이익 실적

과거 기준 점검 0/6

Sarepta Therapeutics은 연평균 21.8%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 29.1%의 비율로 증가했습니다. 매출은 연평균 31.2%의 비율로 증가했습니다.

핵심 정보

21.81%

순이익 성장률

25.72%

주당순이익(EPS) 성장률

Biotechs 산업 성장률17.04%
매출 성장률31.15%
자기자본이익률-62.55%
순이익률-32.45%
다음 순이익 업데이트06 May 2026

최근 과거 실적 업데이트

Recent updates

SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential

Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.

SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals

Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.

Sarepta Therapeutics: A $2B Business Priced Like It's Broken

Mar 24

SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset

Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.

SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution

The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.

SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang

The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.

SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside

Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.

SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside

Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.

SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside

Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.

SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions

The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.

SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance

Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

Dec 04
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise

SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects

The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.

SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts

Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

Oct 18
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry

Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust

Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.

Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust

Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

May 29
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right

The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

May 08
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 20
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%

Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty

Mar 18

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Mar 05
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement

Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness

Mar 04

These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Jan 22
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Jan 16

Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 13
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News

Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

Oct 20
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?

매출 및 비용 세부 내역

Sarepta Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:SRPT 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Dec 252,198-7134920
30 Sep 252,414-2725270
30 Jun 252,482-585640
31 Mar 252,233-2485640
31 Dec 241,9022355580
30 Sep 241,6401225260
30 Jun 241,505475180
31 Mar 241,403174980
31 Dec 231,243-5364820
30 Sep 231,105-6914710
30 Jun 231,003-9084550
31 Mar 23976-1,1154900
31 Dec 22933-7034510
30 Sep 22876-7164090
30 Jun 22835-5073650
31 Mar 22766-3572830
31 Dec 21702-4192830
30 Sep 21646-4862910
30 Jun 21600-6343050
31 Mar 21573-7043060
31 Dec 20540-5543180
30 Sep 20495-6013130
30 Jun 20450-5303130
31 Mar 20407-6563070
31 Dec 19381-7152850
30 Sep 19365-6202680
30 Jun 19345-5702450
31 Mar 19323-4032270
31 Dec 18301-3622080
30 Sep 18274-2451780
30 Jun 18241-2161530
31 Mar 18203-1701330
31 Dec 17155-51123166
30 Sep 17103-1151050
30 Jun 1757-124990
31 Mar 1722-123870
31 Dec 165-267810
30 Sep 161-243850
30 Jun 161-239780
31 Mar 161-218730
31 Dec 151-220660
30 Sep 150-200550
30 Jun 151-177530

양질의 수익: SRPT 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SRPT는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: SRPT는 수익성이 없지만 지난 5년 동안 연평균 21.8%의 속도로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 SRPT의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SRPT은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(50.1%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: SRPT는 현재 수익성이 없으므로 자본 수익률이 음수(-62.55%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/04/30 10:15
종가2026/04/30 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sarepta Therapeutics, Inc.는 49명의 분석가가 다루고 있습니다. 이 중 20명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Brian SkorneyBaird
Huidong WangBarclays
Eliana MerleBarclays